Phoenux AG is a Switzerland-based developer of new medications for the drug substitution market.Mundipharma International Limited, the UK-based pharmaceutical company developing new drugs and patented formulations to relieve chronic pain, oncology and respiratory treatments, has agreed to acquire majority stake in Phoenux AG, the Switzerland-based developer of new medications for the drug substitution market, for an undisclosed consideration.
The acquisition will enable Mundipharma to develop opiod substitutes. The transaction also includes key employees and exclusive global rights to Phoenux patents.
UPDATE 28 October 2014: Mundipharma International Limited has completed the majority stake acquisition of Phoenux AG.
DZ BANK AG
Advised in the sale of
Phoenux AG
to